Phase II Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Oesophageal Squamous Carcinoma After Failure of Conventional Chemotherapy

Trial Profile

Phase II Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Oesophageal Squamous Carcinoma After Failure of Conventional Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Icotinib (Primary)
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
    • 21 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2017.
    • 18 Feb 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top